Protalix Biotherapeutics Inc
PLX1.490USD
+0.040+2.76%
Market hours （ET）Quotes delayed by 15 min
116.42MMarket Cap
29.79P/E TTM
More Details of Protalix Biotherapeutics Inc Company
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.
Company Info
Ticker SymbolPLX
Company nameProtalix Biotherapeutics Inc
IPO dateSep 06, 2010
CEOMr. Dror Bashan
Number of employees207
Security typeOrdinary Share
Fiscal year-endSep 06
Address2 University Plaza
CityHACKENSACK
Stock exchangeEuronext Paris
CountryUnited States of America
Postal code07601
Phone12016969345
Websitehttps://protalix.com/
Ticker SymbolPLX
IPO dateSep 06, 2010
CEOMr. Dror Bashan
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Dror Bashan
Mr. Dror Bashan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.28M
--
Mr. Eyal Rubin
Mr. Eyal Rubin
Chief Financial Officer, Senior Vice President, Treasurer, Secretary
Chief Financial Officer, Senior Vice President, Treasurer, Secretary
660.91K
+15.95%
Mr. Yaron Naos
Mr. Yaron Naos
Senior Vice President - Operations
Senior Vice President - Operations
207.30K
--
Dr. Aharon Schwartz, Ph.D.
Dr. Aharon Schwartz, Ph.D.
Independent Director
Independent Director
174.00K
--
Ms. Gwen A. Melincoff
Ms. Gwen A. Melincoff
Independent Director
Independent Director
40.00
--
Dr. Pol F. Boudes, M.D.
Dr. Pol F. Boudes, M.D.
Independent Director
Independent Director
40.00
--
Mr. Mike Moyer
Mr. Mike Moyer
Investor Relations
Investor Relations
--
--
Mr. Amos Bar Shalev
Mr. Amos Bar Shalev
Independent Director
Independent Director
--
--
Dr. Shmuel (Muli) Ben-Zvi, Ph.D.
Dr. Shmuel (Muli) Ben-Zvi, Ph.D.
Independent Director
Independent Director
--
--
Dr. Eliot Richard Forster, Ph.D.
Dr. Eliot Richard Forster, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Dror Bashan
Mr. Dror Bashan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.28M
--
Mr. Eyal Rubin
Mr. Eyal Rubin
Chief Financial Officer, Senior Vice President, Treasurer, Secretary
Chief Financial Officer, Senior Vice President, Treasurer, Secretary
660.91K
+15.95%
Mr. Yaron Naos
Mr. Yaron Naos
Senior Vice President - Operations
Senior Vice President - Operations
207.30K
--
Dr. Aharon Schwartz, Ph.D.
Dr. Aharon Schwartz, Ph.D.
Independent Director
Independent Director
174.00K
--
Ms. Gwen A. Melincoff
Ms. Gwen A. Melincoff
Independent Director
Independent Director
40.00
--
Dr. Pol F. Boudes, M.D.
Dr. Pol F. Boudes, M.D.
Independent Director
Independent Director
40.00
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jul 23
Updated: Wed, Jul 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
HIR Investments Ltd
5.92%
Bashan (Dror)
2.87%
Renaissance Technologies LLC
1.49%
Millennium Management LLC
1.21%
Susquehanna International Group, LLP
1.08%
Other
87.43%
Shareholders
Shareholders
Proportion
HIR Investments Ltd
5.92%
Bashan (Dror)
2.87%
Renaissance Technologies LLC
1.49%
Millennium Management LLC
1.21%
Susquehanna International Group, LLP
1.08%
Other
87.43%
Shareholder Types
Shareholders
Proportion
Corporation
6.22%
Investment Advisor
4.67%
Individual Investor
4.18%
Hedge Fund
3.67%
Investment Advisor/Hedge Fund
2.30%
Research Firm
0.82%
Pension Fund
0.26%
Venture Capital
0.05%
Other
77.84%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
182
17.64M
22.16%
+1.73M
2025Q1
182
19.45M
25.30%
+4.26M
2024Q4
169
15.65M
21.26%
-1.03M
2024Q3
162
14.11M
19.17%
-5.41M
2024Q2
163
16.36M
22.25%
-4.44M
2024Q1
143
16.45M
23.43%
-4.40M
2023Q4
145
17.20M
24.67%
-3.21M
2023Q3
142
16.45M
24.08%
-6.46M
2023Q2
132
16.38M
24.76%
-4.13M
2023Q1
95
13.57M
27.32%
-11.07M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
HIR Investments Ltd
4.71M
5.92%
--
--
Apr 30, 2025
Bashan (Dror)
2.28M
2.87%
--
--
Apr 30, 2025
Renaissance Technologies LLC
1.19M
1.49%
+70.95K
+6.35%
Mar 31, 2025
Millennium Management LLC
963.01K
1.21%
+575.09K
+148.25%
Mar 31, 2025
Susquehanna International Group, LLP
858.65K
1.08%
+858.65K
--
Mar 31, 2025
Northern Trust Global Investments Limited
683.30K
0.86%
-46.98K
-6.43%
Mar 31, 2025
Rubin (Eyal)
660.91K
0.83%
+90.91K
+15.95%
Apr 30, 2025
Marshall Wace LLP
615.09K
0.77%
+513.19K
+503.62%
Mar 31, 2025
Connor, Clark & Lunn Investment Management Ltd.
482.88K
0.61%
+482.88K
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Growth ETF
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0.01%
Franklin US Small Cap Multifactor Index ETF
0.01%
DFA Dimensional US Sustainability Core 1 ETF
0%
Proshares Ultra Russell 2000
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 Value ETF
0%
Avantis International Small Cap Equity ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.02%
iShares Russell 2000 Growth ETF
Proportion0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
Proportion0.01%
Franklin US Small Cap Multifactor Index ETF
Proportion0.01%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Global X Russell 2000 ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
Avantis International Small Cap Equity ETF
Proportion0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
